Long-term response to relacorilant plus nab-paclitaxel in a patient with metastatic vulvar cancer: a case report
The infrequency of cases, limited guidelines, and lack of robust trials have delayed therapeutic advancements in vulvar cancer, a rare gynecologic malignancy. Here, we present a case of a 52-year-old woman with human papillomavirus–positive vulvar squamous cell carcinoma with metastases to the lung. After experiencing disease progression despite surgery and different chemotherapy combinations, smuhe enrolled in a phase I trial of relacorilant, a selective glucocorticoid receptor antagonist, plus nab-paclitaxel treatment. She experienced a remarkable response to this treatment regimen and has maintained long-term benefit for >8 years.
Authors
- Adrian M. Jubb (ORCID: https://orcid.org/0009-0002-8252-3114)
- Pamela N. Münster (ORCID: https://orcid.org/0000-0002-2074-0984)
- M. Howell
- K. Walker
- E.S. Tsang
- S. Calabrese
- E. Zigman
- P. Lam
- J. Russell
- V. Monga
Institutions
- University of California, San Francisco (US)
- Princess Margaret Cancer Centre (CA)
- Corcept Therapeutics (United States) (US)
Publication Details
- Journal
- ESMO rare cancers.
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1016/j.esmorc.2026.100561
- Primary Topic
- Genital Health and Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00